.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent breakthroughs in genetics are finally addressing the stagnant 30% rate of pharmacoresistant epilepsy by identifying personalized epilepsy treatment targets. While traditional antiseizure drugs only manage symptoms, new precision therapies focus on the underlying molecular causes. These advancements specifically benefit patients with developmental and epileptic encephalopathies (DEEs) who have historically lacked effective options. Furthermore, these strategies mark a shift from purely symptomatic care toward true disease modification.
Scientists are increasingly utilizing antisense oligonucleotides (ASOs) to modulate gene expression at the mRNA level. Consequently, this approach allows for the correction of specific protein deficiencies or the suppression of harmful gain-of-function variants. For instance, recent clinical data for Dravet syndrome have shown significant seizure reduction using targeted ASO chemistry. Moreover, allele-specific designs ensure that only the pathological variant is addressed, preserving healthy gene function in the brain.
Unlike conventional medications, these novel therapies hold the promise of disease modification. Researchers now target causative genes and molecular protein pathways to alter the course of epileptogenesis itself. Additionally, expert opinions suggest that the future of epilepsy care will involve a combination of small molecules and tailored gene therapies. Therefore, identifying the exact genetic signature of a patient is becoming a vital step in managing refractory cases. Identifying these pathways earlier can prevent long-term cognitive and behavioral comorbidities.
Standard drugs generally suppress electrical activity across the brain to stop seizures. In contrast, precision targets address the specific genetic or molecular defect causing the epilepsy in that individual patient.
Currently, gene therapies primarily target monogenic epilepsies and rare developmental encephalopathies. However, research is expanding to identify common genetic variants that may influence drug resistance in more common focal epilepsies.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Explore how genetic advancements and antisense oligonucleotides are shifting epilepsy care from symptomatic relief to precision disease modification....
7 months ago
Targeting ferroptosis provides a compelling strategy to dismantle hypoxia- and acidosis-driven immunosuppression in solid tumors, enhancing response to modern immunotherapy.
Today
Findings from Project Viva indicate that sustained postpartum weight retention, rather than excessive gestational weight gain alone, directly worsens women's mid-life cardiovascular health, degrading blood pressure and glycemic parameters decades after delivery.
Today
A large UK Biobank study reveals that plasma proteomic signatures capture preclinical organ damage and improve multiorgan risk prediction across early CKM syndrome stages 0 to 2 beyond traditional PREVENT clinical models.
Today
A retrospective CBCT study reveals that superior TMJ space asymmetry correlates moderately with occipital condyle-atlas-axis asymmetry in unilateral TMJ osteoarthritis, highlighting an imaging correlate between jaw biomechanics and upper cervical alignment rather than a standalone diagnostic marker.
Today
A Bayesian multilevel meta-analysis reveals that aerobic training combined with moderate carbohydrate restriction modestly lowers HbA1c in type 2 diabetes. However, sparse data and very low certainty leave incremental benefits over exercise or diet alone unproven, highlighting the need for individualized care.
Today
